DS
NBIX icon

DRW Securities’s Neurocrine Biosciences NBIX Stock Holding History

DRW Securities’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,811
Closed -$399K – 1593
2025
Q4 		$399K Buy
+2,811
New +$407K 0.01% 543
2023
Q4 		– Sell
-2,700
Closed -$304K – 409
2023
Q3 		$304K Buy
+2,700
New +$284K 0.01% 262
2014
Q1 		– Sell
-19,000
Closed -$177K – 202
2013
Q4 		$177K Buy
+19,000
New +$185K 0.01% 190

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's NBIX Position: Q1 2026 in Review

DRW Securities sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,811 shares — an estimated $399K sold.

DRW Securities first reported a position in NBIX in Q4 2013 and held it in 3 quarters. The position peaked at $399K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • DRW Securities reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 2,811 Neurocrine Biosciences shares in Q1 2026, an estimated $399K.
  • DRW Securities first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 3 quarters.
  • DRW Securities's Neurocrine Biosciences position peaked at $399K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.